Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Long-Term Results Using the Anatomic Medullary Locking Hip ProsthesisClinical Orthopaedics and Related Research, 2001
- Alendronate Reduces Periprosthetic Bone Loss After Uncemented Primary Total Hip Arthroplasty: A Prospective Randomized StudyJournal of Bone and Mineral Research, 2001
- Effect of Pamidronate in Preventing Local Bone Loss After Total Hip Arthroplasty: A Randomized, Double-Blind, Controlled TrialJournal of Bone and Mineral Research, 2001
- Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic WomenThe Journal of Clinical Endocrinology & Metabolism, 2000
- Skeletal Response to Well Fixed Femoral Components Inserted With and Without CementClinical Orthopaedics and Related Research, 1996
- Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosisBone, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Determinants of Stress ShieldingClinical Orthopaedics and Related Research, 1992
- Producing and Avoiding Stress ShieldingClinical Orthopaedics and Related Research, 1992
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990